Ribonucleic Acid Interference (RNAi) Medicine Market Global Report 2026

The ribonucleic acid interference (RNai) medicine market size has grown rapidly in recent years. It will grow from $4.06 billion in 2025 to $4.79 billion in 2026 at a compound annual growth rate (CAGR) of 18.0%. The growth in the historic period can be attributed to discovery of rna interference mechanism, early-stage clinical trial failures in oligonucleotide therapies, improvements in rna synthesis and stabilization technologies, rise of antisense oligonucleotide research, increasing funding for rare disease research initiatives.

The ribonucleic acid interference (RNai) medicine market size is expected to see rapid growth in the next few years. It will grow to $9.17 billion in 2030 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to expansion of regulatory approvals for rna based therapeutics, increasing pipeline of targeted gene silencing drugs, growing adoption of advanced delivery platforms improving cellular uptake, rising orphan drug incentives across global markets, reduction in manufacturing and synthesis costs of oligonucleotide therapies. Major trends in the forecast period include advancement in targeted delivery vectors for rna silencing therapeutics, expansion of long-acting and sustained release rna interference formulations, increasing focus on off-target effect reduction and safety profiling, growing adoption of combination therapies integrating rna interference with monoclonal antibodies and small molecules, expansion into rare genetic disorder treatment indications.

The growing adoption of personalized medicine is expected to drive the growth of the RNAi medicine market going forward. Personalized medicine is a healthcare approach that customizes disease prevention, diagnosis, and treatment according to an individual's genetic profile, lifestyle, and biological characteristics. The adoption of personalized medicine is increasing due to the expanding use of genetic testing and genomic sequencing technologies, which allow healthcare providers to identify individual genetic variations and deliver more accurate, targeted therapies that enhance patient outcomes. RNAi medicine contributes to personalized medicine by enabling targeted gene silencing based on a patient's unique genetic profile and underlying disease mechanism, supporting the development of precision therapies that improve treatment effectiveness while reducing side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and healthcare organization, the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, compared to six approvals in 2022. Therefore, the growing adoption of personalized medicine is driving the growth of the RNAi medicine market.

Major companies operating in the RNAi medicine market are prioritizing technological innovations, such as stimuli-responsive siRNA platforms, to strengthen targeted gene silencing, increase therapeutic precision, and reduce off-target effects in disease treatment. Stimuli-responsive siRNA platforms are advanced RNA interference delivery technologies engineered to activate or release small interfering RNA (siRNA) in response to specific biological or environmental stimuli, including pH variations, enzymes, temperature changes, or disease-specific biomarkers. For instance, in March 2023, Switch Therapeutics Inc., a US-based biotechnology company, introduced the Conditionally Activated siRNA (CASi) platform, a stimuli-responsive siRNA technology. It improves targeted gene silencing, enhances therapeutic precision, and minimizes off-target effects in RNA interference (RNAi)-based therapies for central nervous system disorders. The CASi (Conditionally Activated siRNA) platform incorporates a first-of-its-kind conditional activation mechanism that keeps siRNA therapies inactive until they reach specific disease-associated cellular environments.

In September 2025, Novartis AG, a Switzerland-based pharmaceutical company, entered into a partnership with Shanghai Argo Biopharmaceutical Co., Ltd. to develop and commercialize RNA interference therapeutics targeting cardiometabolic diseases. Through this partnership, the companies aimed to combine Novartis’ global expertise in drug development and commercialization with Argo’s RNA interference (RNAi) platform technologies to accelerate the development of innovative RNAi-based therapies and expand treatment options for patients with chronic cardiometabolic disorders. Shanghai Argo Biopharmaceutical Co., Ltd. is a China-based biotechnology company focused on developing RNA interference therapeutics and gene-silencing technologies for cardiovascular, metabolic, and other chronic diseases.

Major companies operating in the ribonucleic acid interference (rnai) medicine market report are F. Hoffmann-La Roche Ltd., Novartis AG, Novo Nordisk A/S, Sirius Therapeutics Inc., Alnylam Pharmaceuticals Inc., Switch Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Silence Therapeutics plc, Vir Biotechnology Inc., Arbutus Biopharma Corporation, City Therapeutics Inc., ADARx Pharmaceuticals Inc., Comanche Biopharma Corp., Sirnaomics Ltd., OliX Pharmaceuticals Inc., Nitto BioPharma Inc., Benitec Biopharma Inc., Phio Pharmaceuticals Corp., Ionis Pharmaceuticals, Sarepta Therapeutics, Regeneron Pharmaceuticals, Sanofi, GSK plc.

North America was the dominating region in the ribonucleic acid interference (RNAi) medicine market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the ribonucleic acid interference (RNAi) medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ribonucleic acid interference (RNAi) medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.